Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Apr 8;60(7):1186-8.
doi: 10.1212/01.wnl.0000055087.96356.bb.

Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

J Jankovic  1 , K D Vuong, J Ahsan
Affiliations
Clinical Trial

Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

J Jankovic et al. Neurology. .

Abstract

The authors compared 130 patients treated for cervical dystonia with original botulinum toxin (BTX) type A (Botox; Allergan, Inc., Irvine, CA), 42 of whom were exposed only to the original BTX type A used before 1998 (25 ng protein/100 units), and 119 treated only with the current BTX type A (5 ng of protein/100 units). Blocking antibodies were detected in 4 of 42 (9.5%) patients treated only with original BTX type A but in none of the 119 patients treated exclusively with current BTX type A (p < 0.004). The current preparation decreased the risk of antibody formation by a factor of six. The authors conclude that the low risk of antibody formation after current BTX type A treatment is related to lower protein load.

PubMed Disclaimer

Substances